Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as a whole, comprising the largest, most robust program ever conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection (rCDI) Only gut microbiome research program with five clinical studies demonstrating consistent safety, efficacy and […]
Press Releases
Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021
Analysis of data from five RBX2660 prospective studies is one of only four abstracts to receive the coveted IDWeek 2021 Program Committee Choice award for outstanding scientific research. Ferring and Rebiotix will present new data showing an association between clinical outcomes and restoration of the microbiome Research from the Phase 3 PUNCH CD3 trial on […]
Ferring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study of Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
Interim analysis of the Phase 3 PUNCH™ CD3-Open-Label Study (OLS) showed positive efficacy and consistent safety with RBX2660 for up to six months in patients with recurrent Clostridioides difficile (C. difficile) infection, adding to robust evidence of largest clinical development program in microbiome-based therapeutics Expanded inclusion criteria allowed for enrollment of patients with C. difficile infection typically seen in clinical […]
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is the first microbiota-based live biotherapeutic to demonstrate efficacy as early as first recurrence of Clostridioides difficile (C. difficile) infection RBX2660 Phase 3 data add to the world’s largest and most robust clinical program ever conducted in the field […]
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
The collaboration aims to create standardised, stabilised live microbiota-based formulations addressing bacterial vaginosis (BV), a common vaginal infection among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues1,2,3 The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this patient community and help more […]